A healthtech investor
‍with a mission.

The SFDR has been established in March 2021 by the European Commission. The goal is to support asset owners to compare, select and monitor the sustainability characteristics of investment funds by standardizing disclosures. MTIP Fund II and future funds are classified SFDR Art. 9 targeting social investments that deliver strong financial as well as social impact.

Moreover, we use additional metrics for measuring and mitigating potential negative impacts on the planet and society stemming from our investments. Necessary KPIs are tracked and reported under SFDR Art. 9 to ensure the Principal Adverse Impact and Do No Significant Harm (“DNSH”).  

Our specific SFDR disclosures are published on the investor portal.

Availability
Availability means that a certain health-related good or service is available in a sufficient quantity.

Potential targets: Capacity to provide services, Partnerships & Distribution

Accessibility
Accessibility means that health facilities, goods and services have to be accessible to everyone without discrimination.

Potential targets: Geographical accessibility, Financial accessibility

Acceptability
All health facilities, goods and services must be respectful of medical ethics and culturally appropriate. This includes being designed to respect confidentiality and improve the health status of those concerned.

Potential targets: Patient engagement &     empowerment, Cultural competence & language access

Quality
Health facilities, goods and services must be scientifically and medically appropriate and of good quality.

Potential targets: Patient experience & satisfaction, Clinical effectiveness & safety

MTIP as long-term investor in healthtech understands that value creation and social responsibility go hand-in-hand: both are critical to creating successful and sustainable businesses.